A randomised, blind, placebo controlled crossover study of the influence of the HCN channel-blocker ivabradine on the symptoms of neuropathic pain.
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2013
At a glance
- Drugs Ivabradine (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- 31 Jan 2012 Status changed from recruiting to completed as reported by EudraCT.
- 19 Oct 2011 New trial record